Biomea Fusion(BMEA) - 2025 Q1 - Quarterly Results

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Exhibit 99.1 • Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapy REDWOOD CITY, Calif., May 5, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (Nasdaq: BMEA), a ...